Gwamnatoci a duk faɗin duniya sun ƙarfafa tare da aiwatar da wani sabon nau'i na rarrabuwa dangane da matsayin rigakafin. Wannan ba wai kawai rashin mutuntawa ba ne mai haɗari; babu wani tushe na kimiyya akan haka.
Da alama akwai wani zato mai tushe a nan cewa waɗanda ba a yi musu allurar ba ba su da tsabta (ko da kuwa rigakafi na halitta) kuma kasancewarsu zai yada cuta. Me zai faru idan, duk da haka, binciken da ake ciki ya nuna cewa babu ɗan bambanci tsakanin COVID da aka yi wa alurar riga kafi da rashin alurar riga kafi dangane da kamuwa da cutar, ɗaukar kwayar cutar (nauyin hoto a cikin baka da nasopharynx), da watsa ta?
Kamar yadda ya shafi Omicron, ƙananan ƙananan binciken farko guda biyu na baya-bayan nan sun nuna cewa kashi 80% na shari'ar omicron an yi musu allurar sau biyu. Wilhelm et al. an ba da rahoto game da raguwar bambance-bambancen SARS-CoV-2 omicron ta hanyar rigakafin sera da ƙwayoyin rigakafin monoclonal. "a vitro Binciken da aka yi amfani da ingantattun bambance-bambancen SARS-CoV-2 sun nuna cewa sabanin bambance-bambancen Delta da ke yawo a halin yanzu, tasirin tasirin maganin rigakafin rigakafin rigakafin cutar Omicron ya ragu sosai yana nuna rigakafi ta hanyar T-cell a matsayin muhimmin shinge don hana mummunan COVID-19. ” Bugu da ari, da CDC ta ruwaito akan cikakkun bayanai na shari'o'i 43 na COVID-19 waɗanda aka danganta ga bambance-bambancen Omicron. Sun gano cewa "34 (79%) sun faru a cikin mutanen da suka kammala jerin farko na maganin FDA-izni ko amincewa da maganin COVID-19 kwanaki 14 kafin bayyanar alama ko samun ingantaccen sakamakon gwajin SARS-CoV-2."
Kamar yadda yake da alaƙa da allurar rigakafi da waɗanda ba a yi musu ba suna kama da kamuwa da cuta, nauyin ƙwayar cuta, da ƙarfin watsawa, don haka babu wata hujja mai tushe da za ta raba su a cikin al'umma, musamman muna mai da hankali kan kuma gabatar da (kuma dangane da bambance-bambancen bayanan Delta) jikin shaida.
1) Salvatore et al. sun yi nazari kan yuwuwar watsa allurar rigakafi da marasa lafiya wadanda suka kamu da cutar ta SARS-CoV-2 Delta a cikin gidan yarin tarayya, Yuli-Agusta 2021. Sun gano jimillar samfuran 978 da mahalarta 95 suka bayar, “wanda 78 (82%) sun sami cikakkiyar allurar rigakafi kuma 17 (18%) bai kamata a yi musu allurar rigakafi ba… Mutanen da suka kamu da cutar ta SARS-CoV-2 ba za su iya kamuwa da cutar ba fiye da waɗanda ba a yi musu allurar ba.
2) Singanayagam et al. yayi nazarin watsawa da motsin motsin ƙwayar cuta a cikin mutanen da aka yi wa alurar riga kafi da waɗanda ba a yi musu ba tare da kamuwa da cuta mai sauƙi a cikin al'umma. Sun gano cewa (a cikin abokan hulɗar al'umma 602 (wanda aka gano ta hanyar tsarin bin diddigin kwangilar Burtaniya) na 471 UK COVID-19 index lokuta an ɗauke su zuwa kimantawar watsawa da kamuwa da cutar ta COVID-19 a cikin binciken ƙungiyar lambobin sadarwa kuma sun ba da gudummawar samfuran 8145 na sama na numfashi daga samfuran yau da kullun har zuwa kwanaki 20 na kamuwa da cuta. Duk da haka, mutanen da ke da cikakkiyar rigakafin kamuwa da cuta suna da nauyin ƙwayar cuta mai kama da waɗanda ba a yi musu allurar ba kuma suna iya watsa kamuwa da cuta yadda ya kamata a cikin saitunan gida, gami da cikakkiyar allurar rigakafin.
3) Chia et al. ya ruwaito cewa ƙimar sake zagayowar PCR (Ct) sun kasance "daidai tsakanin duka ƙungiyoyin alurar riga kafi da marasa alurar riga kafi a ganewar asali, amma nauyin ƙwayar cuta ya ragu da sauri a cikin mutanen da aka yi wa alurar riga kafi. Tun da farko, an lura da ingantaccen haɓakar ƙwayoyin rigakafin ƙwayoyin cuta a cikin marasa lafiya da aka yi wa alurar riga kafi, duk da haka, waɗannan titers sun kasance ƙasa da ƙasa da B.1.617.2 idan aka kwatanta da allurar daji.
4) Isra'ila, 2021 duba Babban karatu na lalata titer na antibody bayan maganin BNT162b2 mRNA ko kamuwa da SARS-CoV-2, kuma an ruwaito kamar yadda "Don tantance kinetics na SARS-CoV-2 IgG rigakafi bayan gudanar da allurai biyu na rigakafin BNT162b2, ko kamuwa da cutar SARS-CoV-2 a cikin mutanen da ba a yi musu allurar rigakafi ba… Batun 40% suna da matakan antibody a ƙasa da matakin sero-tabbatacce na <5 AU/ml, yayin da kawai 162% na marasa lafiya da ke fama da rashin lafiya sun kasance ƙasa da <2 AU/ml kofa bayan watanni 16.1 daga kamuwa da SARS-CoV-50.
5) A cikin Rahoton Kula da rigakafin COVID-19 na Burtaniya na mako #42, an lura cewa akwai "ƙasa martanin N antibody akan lokaci" da "cewa matakan N antibody sun yi ƙasa da mutanen da suka kamu da kamuwa da cuta bayan allurai 2 na alluran rigakafi." Rahoton guda ɗaya (Table 2, shafi na 13), ya nuna cewa a cikin tsofaffin rukunin shekaru sama da 30, mutane biyun da aka yi wa allurar rigakafi suna da haɗarin kamuwa da cuta fiye da waɗanda ba a yi musu allurar ba, mai yiwuwa saboda ƙungiyar ta ƙarshe ta haɗa da ƙarin mutane waɗanda ke da ƙaƙƙarfan rigakafi na halitta daga cutar ta Covid. Duba kuma UK PHE ta ba da rahoton 43, 44, 45, 46 don irin wannan bayanai.
6) Barnstable, Massachusetts. Brown et al. An gano cewa a cikin shari'o'i 469 na COVID-19, kashi 74% an yi musu cikakkiyar allurar rigakafi, kuma "wadanda aka yi musu allurar sun fi yawan kwayar cutar a hanci fiye da wadanda ba a yi musu allurar ba."
7) Riemersma et al. An gano "babu wani bambanci a cikin nau'in kwayar cutar yayin kwatanta wadanda ba a yi wa allurar rigakafi da wadanda ke da allurar rigakafin cutar ba." Bugu da ƙari kuma, mutanen da ke fama da ciwon maganin rigakafi akai-akai suna gwada inganci tare da nauyin hoto mai kama da ikon zubar da ƙwayoyin cuta." Sakamako sun nuna cewa "idan mutanen da aka yi musu allurar sun kamu da bambance-bambancen delta, suna iya zama tushen watsa SARS-CoV-2 ga wasu." Sun ba da rahoton "ƙananan ƙimar Ct (<25) a cikin 212 na 310 da aka yi cikakken alurar riga kafi (68%) da 246 na 389 (63%) marasa alurar riga kafi. Gwajin wani yanki na waɗannan ƙananan samfuran Ct ya nuna kamuwa da cutar SARS-CoV-2 a cikin 15 na 17 samfurori (88%) na mutane 37 da ba a yi musu allurar rigakafi mutane."
8) Yin watsi da haɗarin kamuwa da cuta, ganin cewa wani ya kamu da cutar. Acharya et al. An gano "babu wani babban bambanci a cikin ƙimar ƙimar zagayowar tsakanin allurar rigakafi da marasa alurar riga kafi, asymptomatic da ƙungiyoyi masu alamun kamuwa da SARS-CoV-2 Delta."
9) Gazit et al. daga cikin Isra'ila ya nuna cewa "alurar rigakafin SARS-CoV-2-naïve suna da ninki 13 (95% CI, 8-21) ya karu don kamuwa da cuta tare da bambance-bambancen Delta idan aka kwatanta da waɗanda suka kamu da cutar a baya."
-
Dokta Paul Alexander masanin cututtukan cututtuka ne da ke mai da hankali kan cututtukan cututtuka na asibiti, magungunan shaida, da hanyoyin bincike. Yana da digiri na biyu a fannin ilimin cututtuka daga Jami'ar Toronto, sannan ya yi digiri na biyu a Jami'ar Oxford. Ya sami PhD ɗinsa daga Hanyoyi, Shaida, da Tasirin Ma'aikatar Lafiya ta McMaster. Yana da wasu horo na asali a Bioterrorism/Biowarfare daga John's Hopkins, Baltimore, Maryland. Paul tsohon mai ba da shawara ne na WHO kuma babban mai ba da shawara ga Sashen HHS na Amurka a cikin 2020 don amsawar COVID-19.
Duba dukkan posts
